Experience of treatment of lung cancer patients using paclitaxel and carboplatin
Abstract
Abstrak Sembilan belas pasien kanker paru jenis karsinoma bukan set kecil stage Jll & JV mendapat kemoterapi dengan paduan paklitaksel dan karboplatin di Rumah Sakit Kanker Dharmais dan Rumah Sakit Pusat Pertamina Jakarta, terdiri dari J4 laki-laki dan 5 perempuan. Diagnosis histologis ialah adenokarsinoma pada 13 pasien, karsinoma skuamosa pada 4 pasien dan karsinoma adenoskuamosa pada J pasien. Empat belas pasien termasuk stage JV, stage llJB terlihat pada 4 pasien dan stage 11/A pada 1 pasien. Paduan obat terdiri dari paklitaksel, dengan dosis 135-200 mg/m2 dan karboplatin 300 mg/m2 atau AUC 6 mg/ml.min, diberikan melalui infus setiap 3 minggu, paling sedikit 3 siklus. Pasien diikuti secara teratur sampai meninggal. Respon objektif berupa respon parsial (partial response) terlihat pada 12 pasien (63%), 2 pasien tidak menunjukkan perubahan (stable disease) dan perburukan terlihat pada 5 orang (26%). Dua pasien masih hidup masing-masing 22 dan 23 bulan setelah kemoterapi dimulai. Masa tahan hidup 1 tahun adalah 58%dan masa tengah tahan hidup ialah 14 bulan. Abstract Nineteen patients with stage 111 & IV nonsmall cell lung cancer were treated with regimen containing paclitaxel and carboplatin at Dharmais National Cancer Center Hospital and Pertamina General Hospital, Jakarta - Indonesia. There were 14 males and 5 females, the histologic diagnosis being adenocarcinoma in 13 patients, squamous carcinoma in 5 patients and adenosquamous carcinoma in J patient. Fourteen patients were in stage IV, 4 had stage 11/B, one had stage fl/A disease. The regimen contains paclitaxel 135-200 mg/m2, combined with carboplatin 300 mg/m2 or AUC 6 mg/ml. min, given every 3 weeks. Those who undenvent at least 3 cycles of chemotherapy were followed up until death. Objective improvement (partial response) was seen in 12 patients or 63%; 2 had stable disease (11%) and 5 had progressive disease (26%). Two patients are still alive at 22 months and 23 months after starting chemotherapy. The one year survival rate was 58%and median survival time was 14 months. Keywords: nonsmall cell carcinoma, chemotherapy, paclitaxel, carboplatin The treatmentDownloads
Copyright (c) 2000 Anwar Jusuf, Sutji A. Mariono, Karmel L. Tambunan, A. H. Reksodiputro, Noorwati Soetandyo, Ronald Hukom, Eddy Suratman, A. M. Jayusman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.